Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers

Molecular Cancer Therapeutics

Volumn 16, Issue 5, 2017, Pages 871-878

  Pillow, Thomas H ^a   Schutten, Melissa ^a   Yu, Shang Fan ^a   Ohri, Rachana ^a   Sadowsky, Jack ^a   Poon, Kirsten Achilles ^a,d   Solis, Willy ^a,e   Zhong, Fiona ^a   Del Rosario, Geoffrey ^a   Go, Mary Ann T ^a   Lau, Jeffrey ^a   Yee, Sharon ^a   He, Jintang ^a   Liu, Luna ^a   Ng, Carl ^a   Xu, Keyang ^a   Leipold, Douglas D ^a   Kamath, Amrita V ^a   Zhang, Donglu ^a   Masterson, Luke ^b   Gregson, Stephen J ^b   Howard, Philip W ^b   Fang, Fan ^c   Chen, Jinhua ^c   Gunzner Toste, Janet ^a   Kozak, Katherine K ^a   Spencer, Susan ^a   Polakis, Paul ^a   Polson, Andrew G ^a   Flygare, John A ^a   Junutula, Jagath R ^a,f   more..

^a GENENTECH INC   (United States)

^b ASTRAZENECA   (United Kingdom)

^c WUXI APPTEC   (China)

^d Denali Therapeutics   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f Cellerant Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; DISULFIDE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; METHYL GROUP; PYRROLOBENZODIAZEPINE; SG 3203; SG 3451; UNCLASSIFIED DRUG; ANTIBODY; ANTIBODY CONJUGATE; PYRROLE DERIVATIVE; PYRROLO(2,1-C)(1,4)BENZODIAZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL CHEMISTRY; CLINICAL OBSERVATION; CONTROLLED STUDY; CYCLIZATION; CYTOSOL; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; HEMATOCRIT; HISTOPATHOLOGY; HYDROPHOBICITY; IN VIVO STUDY; LARGE INTESTINE; LEUKOCYTE COUNT; LUNG ALVEOLUS MACROPHAGE; LYMPH NODE; MALE; MOUSE; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; RAT; RETICULOCYTE; SMALL INTESTINE; SPLEEN; THROMBOCYTE; THYMUS; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HUMAN; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISULFIDES; HUMANS; IMMUNOCONJUGATES; MICE; NEOPLASMS; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019990764     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0641     Document Type: Article

References (44)

1. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev 2016;68:3-19.
2. Chari RV. Expanding the reach of antibody-drug conjugates. ACS Med Chem Lett 2016;7:974-76.
3. Liu R, Wang RE, Wang F. Antibody-drug conjugates for non-oncological indications. Expert Opin Biol Ther 2016;16:591-3.
4. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408.
5. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
6. Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, et al. Preclinical profile of the HER2-targeting ADC SYD983/ SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther 2014;13:2618-29.
7. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17:6417-27.
8. Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjugate Chem 2013;24:1256-63.
9. Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, et al. A new class of antibody-drug conjugates with potent DNA alkylating activity. Mol Cancer Ther 2016;15:1870-8.
10. Flygare JA, H PT, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013;81:113-21.
11. Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjugate Chem 2015;26:176-92.
12. Chudasama V, Maruani A, Caddick S. Recent advances in the construction of antibody-drug conjugates. Nat Chem 2016;8:114-9.
13. Akkapeddi P, Azizi SA, Freedy AM, Cal P. Construction of homogeneous antibody-drug conjugates using site-selective protein chemistry. Chem Sci 2016;7:2954-63.
14. Nolting B. Linker technologies for antibody-drug conjugates. Methods Mol Biol 2013;1045:71-100.
15. McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 2015;17: 339-51.
16. Lu J, Jiang F, Lu A, Zhang G. Linkers having a crucial role in antibody-drug conjugates. Int J Mol Sci 2016;17:561.
17. Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res 2015;32:3526-40.
18. Burke PJ, Senter PD, Meyer DW, Miyamoto JB, Anderson M, Toki BE, et al. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjugate Chem 2009; 20:1242-50.
19. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab- DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68: 9280-90.
20. Polson AG, Calemine-Fenaux J, Chan P, ChangW, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69: 2358-64.
21. Pillow TH, Sadowsky JD, Zhang D, Yu S-F, Del Rosario G, Xu K, et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci 2017;8:366-370.
22. Kim MT, Chen Y, Marhoul J, Jacobson F. Statistical modeling of the drug load distribution on trastuzumab emtansine (kadcyla), a lysine-linked antibody drug conjugate. Bioconjugate Chem 2014;25: 1223-32.
23. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010;16:4769-78.
24. Gerratana B. Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev 2012;32:254-93.
25. Xu K, Liu L, Saad OM, Baudys J, Williams L, Leipold D, et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem 2011;412:56-66.
26. Gregson SJ, Howard PW, Gullick DR, Hamaguchi A, Corcoran KE, Brooks NA, et al. Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. J Med Chem 2004; 47:1161-74.
27. Hartley JA,Hamaguchi A, Suggitt M,Gregson SJ, Thurston DE, Howard PW. DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. Invest New Drugs 2011;30:950-8.
28. Zhang D, Pillow TH, Ma Y, Cruz-Chuh JD, Kozak KR, Sadowsky JD, et al. Linker immolation determines cell killing activity of disulfide-linked pyrrolobenzodiazepine antibody-drug conjugates. ACS Med Chem Lett 2016;7:988-93.
29. Zhang D, Yu S-F, Ma Y, Xu K, Dragovich PS, Pillow TH, et al. Chemical structure and concentration of intratumor catabolites determine efficacy of antibody drug conjugates. Drug Metab Dispos 2016;44:1517-23.
30. Satyam A. Design and synthesis of releasable folate-drug conjugates using a novel heterobifunctional disulfide-containing linker. Bioorg Med Chem Lett 2008;18:3196-9.
31. Li D, Poon KA, Yu S-F, Dere R, Go M, Lau J, et al. DCDT2980S, an anti- CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 2013;12: 1255-65.
32. Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, Chuh J, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nature Chem 2016;8:1112-9.
33. Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, et al. Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc 2016;138:1430-45.
34. Kolakowski RV, Haelsig KT, Emmerton KK, Leiske CI, Miyamoto JB, Cochran JH, et al. The methylene alkoxy carbamate self-immolative unit: utilization for the targeted delivery of alcohol-containing payloads with antibody-drug conjugates. Angew Chem Int Ed 2016;55: 7948-51.
35. Kung SutherlandMS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122:1455-63.
36. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7:302ra136.
37. Flynn M, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, et al. ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther 2016;15:2709-21.
38. Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9.
39. Beesley RM, Ingold CK, Thorpe JF. CXIX-the formation and stability of spiro-compounds. Part I. spiro-compounds from cyclohexane. J Chem Soc Trans 1915;107:1080-106.
40. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 2009;106:11937-42.
41. Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG, Denny WA, et al. Design, synthesis, and in vitro evaluation of dipeptide- based antibody minor groove binder conjugates. J Med Chem 2005;48:1344-58.
42. Jeffrey SC, Nguyen MT, Moser RF, Meyer DL, Miyamoto JB, Senter PD. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorg Med Chem Lett 2007;17: 2278-80.
43. Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjugate Chem 2008;19:358-61.
44. Zhao RY, Erickson HK, Leece BA, Reid EE, Goldmacher VS, Lambert JM, et al. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem 2012;55:766-82.